Jefferies Financial Group upgraded shares of BioCryst Pharmaceuticals (NASDAQ:BCRX – Free Report) from a hold rating to a buy rating in a research note published on Friday, Marketbeat reports. Jefferies Financial Group currently has $11.00 price objective on the biotechnology company’s stock. BCRX has been the topic of a number of other research reports. StockNews.com […]